| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.08. | Sysmex GAAP EPS of ¥14.17, revenue of ¥130.67B; updates FY 2027 outlook | 26 | Seeking Alpha | ||
| 07.08. | Sysmex Corporation Announces Increase In Q1 Profit | 690 | AFX News | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) revealed a profit for its first quarter that Increased, from the same period last yearThe company's bottom line totaled JPY8.691 billion, or JPY14.17... ► Artikel lesen | |
| 17.06. | VolitionRx partners with Sysmex to optimize Nu.Q NETs assay | 9 | Seeking Alpha | ||
| 17.06. | VolitionRx und Sysmex kooperieren bei der Entwicklung von Diagnosetests | 5 | Investing.com Deutsch | ||
| 17.06. | VolitionRx Limited: VolitionRx Announces Collaboration with Sysmex | 555 | PR Newswire | HENDERSON, Nev., June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration... ► Artikel lesen | |
| 17.06. | EQS-News: Sysmex Europe SE: Sysmex führt die HISCL Plattform ein, die schnelle, skalierbare Analysen aus Blut für die Alzheimerkrankheit ermöglicht | 593 | EQS Group (DE) | EQS-News: Sysmex Europe SE
/ Schlagwort(e): Produkteinführung/Sonstiges
Sysmex führt die HISCL Plattform ein, die schnelle, skalierbare Analysen aus Blut für die Alzheimerkrankheit... ► Artikel lesen | |
| SYSMEX CORPORATION ADR Aktie jetzt für 0€ handeln | |||||
| 17.06. | Sysmex Europe SE: Sysmex launches HISCL platform, enabling faster, scalable Alzheimer's blood testing | 674 | PR Newswire | HAMBURG, Germany, June 17, 2026 /PRNewswire/ -- Independent European studies presented at CTAD 2025 and ADPD2026 confirmed that the HISCL p-Tau217 RUO* and the HISCL Aß42/40 ratio are highly... ► Artikel lesen | |
| 14.05. | Sysmex meldet Rekordumsatz für Q4 2025, Währungseffekte belasten jedoch den Gewinn | 34 | Investing.com Deutsch | ||
| 14.05. | Sysmex FY Net Profit Declines | 572 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Sysmex (6869.T) reported fiscal year profit attributable to owners of the parent of 35.5 billion yen, a decline of 33.9% from prior year. Operating profit... ► Artikel lesen | |
| 12.05. | neotares realisiert neuen Unternehmenssitz in Hamburg für Sysmex | 2 | DEAL-Magazin | ||
| 16.04. | Sysmex vereint drei Europazentralen auf neuem Hamburger Campus | 24 | Bionity.com | ||
| 14.04. | Sysmex Europe eröffnet offiziell seinen neuen Campus in Hamburg und setzt damit neue Maßstäbe für zukunftsorientierte Arbeitsumgebungen | 760 | news aktuell | Hamburg (ots) - Sysmex Europe hat offiziell seinen neuen Bürocampus in Hamburg-Alsterdorf eröffnet und damit den Umzug seines EMEA-Hauptsitzes von Norderstedt in die Stadt abgeschlossen. Rund 780 Mitarbeiter... ► Artikel lesen | |
| 12.02. | Sysmex Corporation Bottom Line Drops In Nine Months | 833 | AFX News | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) announced a profit for nine months that Dropped, from the same period last yearThe company's earnings came in at JPY33.694 billion, or JPY54.05... ► Artikel lesen | |
| 05.02. | Fujirebio und Sysmex beginnen Vertriebskooperation für Demenz-Tests | 708 | Business Wire | Fujirebio Holdings, Inc. (Zentrale: Minato-ku, Tokio; President CEO: Goki Ishikawa; "Fujirebio"), eine konsolidierte Tochtergesellschaft der H.U. Group Holdings, Inc. (Zentrale: Minato-ku, Tokio;... ► Artikel lesen | |
| 05.11.25 | Sysmex H1 Profit Declines | 1.025 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Sysmex Corporation reported that its first half profit attributable to owners of the
parent was 19.0 billion yen, a decline of 26.9% from prior year. Earnings... ► Artikel lesen | |
| 04.11.25 | Comgest Growth Japan Fonds: Von Sysmex bis Obic - Comgest setzt auf Japans Qualitätstitel | 1.317 | fondscheck.de | Paris (www.fondscheck.de) - Japan ist "in", so Richard Kaye, Portfoliomanager für japanische Aktien bei der Fondsboutique Comgest im Kommentar zum Comgest Growth Japan Fonds (ISIN IE0004767087/ WKN... ► Artikel lesen | |
| 01.10.25 | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | 1.511 | AFX News | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RESMED | 200,00 | -1,14 % | ResMed Stock: Analyst Estimates & Ratings | ||
| CARDINAL HEALTH | 200,10 | -2,20 % | Reasons to Retain Cardinal Health Stock in Your Portfolio for Now | ||
| ZIMMER BIOMET | 86,30 | -0,83 % | Zimmer Biomet Holdings Inc. Q2 Income Rises | WASHINGTON (dpa-AFX) - Zimmer Biomet Holdings Inc. (ZBH) announced a profit for its second quarter that Increases, from last yearThe company's earnings came in at $198.3 million, or $1.03 per... ► Artikel lesen | |
| UNIDOC HEALTH | 0,052 | -12,24 % | UniDoc Health Corp.: UniDoc Health Signs MOU with Ventripoint Diagnostics to Evaluate Remote Cardiac Assessment and Screening Platform | Proposed collaboration would combine UniDoc's connected-care infrastructure with Ventripoint's AI-enabled cardiac imaging platform VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / UniDoc Health Corp.... ► Artikel lesen | |
| CO-DIAGNOSTICS | 1,255 | +0,40 % | Co-Diagnostics Reports Second Quarter 2026 Financial Results | Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion
Strengthening Integrated Co-Dx PCR Platform Through Scientific... ► Artikel lesen | |
| CLARIANE | 3,988 | 0,00 % | Clariane: First-half 2026 results | Half-Year Results: strong improvement in operating performanceSuccessful refinancing transactions Objectives confirmed Strong improvement in operating performance Revenue as at 30 June 2026 stood... ► Artikel lesen | |
| PANGENOMIC HEALTH | 0,199 | -5,24 % | XFRA LL3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| INSPIREMD | 0,780 | +0,65 % | InspireMD Inc.: InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing | MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) ("InspireMD" or the "Company"), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced... ► Artikel lesen | |
| VYOME | 2,280 | 0,00 % | Vyome Holdings, Inc - 8-K, Current Report | ||
| IZOTROPIC | 0,133 | +5,56 % | Izotropic Corporation: Izotropic Executes Formal Agreement with Izotropic Africa for Exclusive Distribution Throughout Africa and the GCC | Vancouver, British Columbia and Casablanca, Morocco--(Newsfile Corp. - July 2, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device... ► Artikel lesen | |
| ORGANOGENESIS | 1,470 | 0,00 % | Johnson & Johnson, GSK und Co.: Warum der Wettlauf um Zelltherapie-Plattformen gerade erst beginnt | ||
| ASTRANA HEALTH | 31,600 | -1,86 % | Astrana Health, Inc. Reports Second Quarter 2026 Results | Company to Host Conference Call on Thursday, August 6, 2026, at 2:30 p.m. PT/5:30 p.m. ET
Reports revenue of $972.5 million, up 49% year-over-year, net income... ► Artikel lesen | |
| CATHETER PRECISION | 0,210 | 0,00 % | Catheter Precision, Inc.: Flyte Surpasses 10,000 Consumer Accounts as WebApp Growth Accelerates | ||
| ORIOLA | 0,886 | 0,00 % | Oriola Corporation: Oriola Corporation's Half-Year Report 1 January-30 June 2026 | Oriola Corporation Stock Exchange Release 17 July 2026 at 8.30 a.m. EEST
Oriola Corporation's Half-Year Report 1 January-30 June 2026
Continued net sales growth in Product segment, Group profitability... ► Artikel lesen | |
| CROSSJECT | 1,564 | 0,00 % | CROSSJECT announces the successful completion of an equity financing and warrant issuance for a total immediate gross amount of €15 million | Provides immediate new financing to support the Company's next strategic milestones Strengthens shareholders' equity and improves the Company's financial structure Supports the continuation of ZEPIZURE®... ► Artikel lesen |